HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Acyl-CoA oxidase deficiency — Clinical Guidelines

Overview

Multiple acyl-CoA dehydrogenase deficiency (MADD) is an inborn error of metabolism affecting fatty acid and amino acid oxidation, leading to metabolic decompensation under stress conditions. It encompasses various subtypes including medium-chain acyl-CoA dehydrogenase deficiency (MCADD), very long-chain acyl-CoA dehydrogenase deficiency (VLCADD), and others, each with distinct clinical presentations and management needs 1 2 4 5 14.

Diagnosis

Clinical Presentation: Hypoketotic hypoglycemia, lethargy, vomiting, cardiomyopathy, and arrhythmias 2 14.

Biochemical Tests: Elevated levels of specific acylcarnitines in blood and urine, particularly C8, C10, and dicarboxylic acids 2 14.

Genetic Testing: Identification of mutations in ETFA, ETFB, ETFDH, or ACADVL genes 1 4 12.

Enzyme Assays: Deficiency in acyl-CoA dehydrogenase activity in fibroblasts or muscle biopsy 1 19.

Newborn Screening: Effective for early detection, especially for MCADD 10.

Management

Acute Management: Immediate provision of glucose, avoidance of fasting, and supportive care including extracorporeal life support if necessary 8 10.

Long-term Treatment:

- Dietary Management: Frequent small meals, avoidance of fasting, and supplementation with medium-chain triglycerides 2 10. - Riboflavin Supplementation: Beneficial in riboflavin-responsive cases, particularly those with ETFDH mutations 4 12. - Carnitine Supplementation: L-carnitine to aid in fatty acid metabolism 11 13. - Ubiquinone (CoQ10): May be considered based on specific deficiencies identified 4 11.

Special Populations

Pediatrics: Close monitoring during intercurrent illnesses, early intervention crucial 2 10.

Pregnancy: Riboflavin therapy in affected mothers can prevent neonatal complications 24.

Comorbidities: Special attention to metabolic stress in patients with additional health issues 18.

Key Recommendations

Implement Newborn Screening for early detection of MCADD and prompt initiation of management strategies (Evidence: Strong 10).

Provide Immediate Glucose Therapy during acute metabolic decompensation to prevent hypoglycemia and support energy needs (Evidence: Moderate 8 10).

Consider Riboflavin Supplementation in riboflavin-responsive cases to improve metabolic profiles and clinical symptoms (Evidence: Moderate 4 12).

Maintain Frequent Nutritional Intake to prevent fasting-induced crises, especially in pediatric patients (Evidence: Expert opinion).

Monitor and Manage Specific Genetic Mutations through tailored dietary and pharmacological interventions based on identified genetic defects (Evidence: Moderate 1 4 12).

References

1 Li Y, Li Y, Liu H, Cheng L, Ma H, Xu X et al.. Generation of a human induced pluripotent stem cell line (LZUSHi002-A) from a MADD patient with ETFDH mutation. Stem cell research 2022. link 2 McGregor TL, Berry SA, Dipple KM, Hamid R. Management Principles for Acute Illness in Patients With Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency. Pediatrics 2021. link 3 Knottnerus SJG, Mengarelli I, Wüst RCI, Baartscheer A, Bleeker JC, Coronel R et al.. Electrophysiological Abnormalities in VLCAD Deficient hiPSC-Cardiomyocytes Can Be Improved by Lowering Accumulation of Fatty Acid Oxidation Intermediates. International journal of molecular sciences 2020. link 4 Vieira P, Myllynen P, Perhomaa M, Tuominen H, Keski-Filppula R, Rytky S et al.. Riboflavin-Responsive Multiple Acyl-CoA Dehydrogenase Deficiency Associated with Hepatoencephalomyopathy and White Matter Signal Abnormalities on Brain MRI. Neuropediatrics 2017. link 5 Li X, Ding Y, Ma Y, Liu Y, Wang Q, Song J et al.. Very long-chain acyl-coenzyme A dehydrogenase deficiency in Chinese patients: eight case reports, including one case of prenatal diagnosis. European journal of medical genetics 2015. link 6 Brown A, Crowe L, Andresen BS, Anderson V, Boneh A. Neurodevelopmental profiles of children with very long chain acyl-CoA dehydrogenase deficiency diagnosed by newborn screening. Molecular genetics and metabolism 2014. link 7 Derks TG, Touw CM, Ribas GS, Biancini GB, Vanzin CS, Negretto G et al.. Experimental evidence for protein oxidative damage and altered antioxidant defense in patients with medium-chain acyl-CoA dehydrogenase deficiency. Journal of inherited metabolic disease 2014. link 8 Kumar G, Mattke AC, Bowling F, McWhinney A, Alphonso N, Karl TR. Resuscitation of a neonate with medium chain acyl-coenzyme a dehydrogenase deficiency using extracorporeal life support. World journal for pediatric & congenital heart surgery 2014. link 9 Jakobs BS, van den Heuvel LP, Smeets RJ, de Vries MC, Hien S, Schaible T et al.. A novel mutation in COQ2 leading to fatal infantile multisystem disease. Journal of the neurological sciences 2013. link 10 Couce ML, Sánchez-Pintos P, Diogo L, Leão-Teles E, Martins E, Santos H et al.. Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: regional experience and high incidence of carnitine deficiency. Orphanet journal of rare diseases 2013. link 11 Rosa M, Pascarella A, Parenti G, Buono S, Romano A, Della Casa R et al.. Developmental evolution in a patient with multiple acyl-coenzymeA dehydrogenase deficiency under pharmacological treatment. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2012. link 12 Cotelli MS, Vielmi V, Rimoldi M, Rizzetto M, Castellotti B, Bertasi V et al.. Riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency with unknown genetic defect. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2012. link 13 van Maldegem BT, Duran M, Wanders RJ, Waterham HR, Wijburg FA. Flavin adenine dinucleotide status and the effects of high-dose riboflavin treatment in short-chain acyl-CoA dehydrogenase deficiency. Pediatric research 2010. link 14 Baruteau J, Levade T, Redonnet-Vernhet I, Mesli S, Bloom MC, Broué P. Hypoketotic hypoglycemia with myolysis and hypoparathyroidism: an unusual association in medium chain acyl-CoA desydrogenase deficiency (MCADD). Journal of pediatric endocrinology & metabolism : JPEM 2009. link 15 Chiong MA, Sim KG, Carpenter K, Rhead W, Ho G, Olsen RK et al.. Transient multiple acyl-CoA dehydrogenation deficiency in a newborn female caused by maternal riboflavin deficiency. Molecular genetics and metabolism 2007. link 16 van Maldegem BT, Duran M, Wanders RJ, Niezen-Koning KE, Hogeveen M, Ijlst L et al.. Clinical, biochemical, and genetic heterogeneity in short-chain acyl-coenzyme A dehydrogenase deficiency. JAMA 2006. link 17 Bok LA, Vreken P, Wijburg FA, Wanders RJ, Gregersen N, Corydon MJ et al.. Short-chain Acyl-CoA dehydrogenase deficiency: studies in a large family adding to the complexity of the disorder. Pediatrics 2003. link 18 Roe CR, Wiltse HE, Sweetman L, Alvarado LL. Death caused by perioperative fasting and sedation in a child with unrecognized very long chain acyl-coenzyme A dehydrogenase deficiency. The Journal of pediatrics 2000. link 19 Coates PM, Indo Y, Young D, Hale DE, Tanaka K. Immunochemical characterization of variant medium-chain acyl-CoA dehydrogenase in fibroblasts from patients with medium-chain acyl-CoA dehydrogenase deficiency. Pediatric research 1992. link 20 Williams SG, Worsham LM, Ernst-Fonberg ML. Purification and partial characterization of acyl carrier protein from Euglena gracilis variety bacillaris. Protein expression and purification 1991. link90072-q) 21 Indo Y, Coates PM, Hale DE, Tanaka K. Immunochemical characterization of variant long-chain acyl-CoA dehydrogenase in cultured fibroblasts from nine patients with long-chain acyl-CoA dehydrogenase deficiency. Pediatric research 1991. link 22 Fukui K, Momoi K, Watanabe F, Miyake Y. In vivo and in vitro expression of porcine D-amino acid oxidase: in vitro system for the synthesis of a functional enzyme. Biochemistry 1988. link 23 Mozaffar S, Ueda M, Kitatsuji K, Shimizu S, Osumi M, Tanaka A. Properties of catalase purified from a methanol-grown yeast, Kloeckera sp. 2201. European journal of biochemistry 1986. link 24 Harpey JP, Charpentier C, Goodman SI, Darbois Y, Lefèbvre G, Sebbah J. Multiple acyl-CoA dehydrogenase deficiency occurring in pregnancy and caused by a defect in riboflavin metabolism in the mother. Study of a kindred with seven deaths in infancy: Value of riboflavin therapy in preventing this syndrome. The Journal of pediatrics 1983. link80410-7)

Acyl-CoA oxidase deficiency